ARTICLE | Financial News
ViaCyte attracts crossover investors for $80M series D
November 30, 2018 6:28 PM UTC
ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies.
ViaCyte President and CEO Paul Laikind declined to disclose the triggers for the financing's two tranches but said they are progress based...